El-Agamy, D. S., El-Harbi, K. M., Khoshhal, S., Ahmed, N., Elkablawy, M. A., Shaaban, A. A., & Abo-Haded, H. M. (2018). Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Manag Res.

El-Agamy, Dina S., Khaled M. El-Harbi, Saad Khoshhal, Nishat Ahmed, Mohamed A. Elkablawy, Ahmed A. Shaaban, and Hany M. Abo-Haded. "Pristimerin Protects against Doxorubicin-induced Cardiotoxicity and Fibrosis Through Modulation of Nrf2 and MAPK/NF-kB Signaling Pathways." Cancer Manag Res 2018.

El-Agamy, Dina S., et al. "Pristimerin Protects against Doxorubicin-induced Cardiotoxicity and Fibrosis Through Modulation of Nrf2 and MAPK/NF-kB Signaling Pathways." Cancer Manag Res 2018.